Asset
MOLGRAMOSTIM
Revenue
No revenue reported in loaded filings.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04544293 | phase3 | active_not_recruiting | 2021-05-19 | 2023-11-30 | Savara Inc. | Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) |
| NCT02702180 | phase2 | completed | 2016-03-21 | 2019-04-19 | Savara Inc. | Efficacy and Safety of Inhaled Molgramostim (rhGM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis |
| NCT02468908 | phase1 | completed | 2015-05-01 | 2015-10-01 | Savara Inc. | Inhaled Molgramostim (rhGM-CSF) in Healthy Adult Subjects |
| NCT06431776 | phase3 | recruiting | 2025-10-22 | 2027-06-01 | Savara Inc. | Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP). |
| NCT03482752 | phase3 | terminated | 2018-04-16 | 2021-01-14 | Savara Inc. | Safety Extension Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis |
FDA applications (0)
This company has no applications containing this asset.